DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives

Complex rearrangement patterns and mitotic errors are hallmarks of most pancreatic ductal adenocarcinomas (PDAC), a disease with dismal prognosis despite some therapeutic advances in recent years. DNA double-strand breaks (DSB) bear the greatest risk of provoking genomic instability, and DNA damage repair (DDR) pathways are crucial in preserving genomic integrity following a plethora of damage…

PanCAN’s Precision Promise Adaptive Clinical Trial Platform Locations – Pancreatic Cancer Action Network

Find out where sites are located across the country for Precision Promise, PanCAN’s groundbreaking platform designed to accelerate new treatment options for pancreatic cancer patients.

KRAS controls pancreatic cancer cell lipid metabolism and invasive potential through the lipase HSL

Oncogene-induced metabolic reprogramming is a hallmark of pancreatic cancer (PDAC), yet the metabolic drivers of metastasis are unclear. In PDAC, obesity and excess fatty acids accelerate tumor growth and increase metastasis. Here, we report that excess lipids, stored in organelles called lipid droplets (LD), are a key resource to fuel the energy-intensive process of metastasis. The oncogene KRAS…

DNA Methylation–Derived Immune Cell Profiles, CpG Markers of Inflammation, and Pancreatic Cancer Risk

Background: Pancreatic cancer is projected to become the second most common cause of cancer-related death over the next 5 years. Because inflammation is thought to be a common trajectory for disease initiation, we sought to prospectively characterize immune profiles using DNA methylation markers and examine DNA methylation levels previously linked to inflammation biomarkers to evaluate whether…

Managing Acute Pancreatitis

Acute pancreatitis can be a devastating disease. Complications of pancreatitis can be minimized by appropriate early, initial management. Joe Hines, MD, and Raman Muthusamy, MD, from UCLA discuss the recent American Gastroenterological Association guideline on managing acute pancreatitis.

Convolutional neural network for the detection of pancreatic cancer on CT scans

We applaud Kao-Lang Liu and colleagues1 for the development of a convolutional neural network (CNN) to classify CT image patches into cancerous and non-cancerous pancreatic tissue groups. Specifically, the patients with abnormal images were those who had histologically confirmed or cytologically confirmed pancreatic adenocarcinoma. In this study, the pancreas and tumours were segmented by two…

Deep learning to distinguish pancreatic cancer tissue from non-cancerous pancreatic tissue: a retrospective study with cross-racial external validation

CNN could accurately distinguish pancreatic cancer on CT, with acceptable generalisability to images of patients from various races and ethnicities. CNN could supplement radiologist interpretation.

A DNA hypomethylating drug alters the tumor microenvironment and improves the effectiveness of immune checkpoint inhibitors in a mouse model of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer that has proven refractory to immunotherapy. Previously, treatment with the DNA hypomethylating drug decitabine (5aza-dC; DAC) extended survival in the KPC-Brca1 mouse model of PDAC. Here we investigated the effects of DAC in the original KPC model and tested combination therapy with DAC followed by immune checkpoint inhibitors (ICI)….

Detecting pancreatic cancer at treatable stages

Pancreatic cancer is rarely detected at its early stages because symptoms often do not present themselves until after the cancer has progressed. By then, invasive procedures such as surgery, chemotherapy or radiation are often needed to treat the cancer.

The Cancer News Daily

The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD